Is Anika Therapeutics, Inc. ANIK stock Halal to invest in?

Yes, as of September 2026, Anika Therapeutics, Inc. stock (ANIK) is classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening Halal stocks. Anika Therapeutics, Inc. currently passes all four AAOIFI financial screens: non-permissible income remains below 5% of total revenue, interest-bearing investments and interest-bearing debt each remain below 30% of market capitalisation, and the company has no impermissible preference share structure. The stock's current purification factor is 100%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Anika Therapeutics, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Anika Therapeutics, Inc. ANIK reviewed for Shariah compliance?

Tabadulat reviews Anika Therapeutics, Inc. ANIK for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Anika Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Anika Therapeutics, Inc. ANIK pass the AAOIFI Non Permissible Income criteria?

Yes, as of September 2026, Anika Therapeutics, Inc. stock (ANIK) passes the AAOIFI non-permissible income screen. In practice this screen asks a simple question: how much of the company's revenue comes from sources Islam prohibits, such as Riba, conventional financial services, alcohol, gambling or tobacco? AAOIFI allows at most 5%, and Anika Therapeutics, Inc. stays below that line this month. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Anika Therapeutics, Inc. ANIK pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of September 2026, Anika Therapeutics, Inc. stock (ANIK) passes the AAOIFI interest-bearing investments screen. This screen looks at where the company parks its cash: conventional deposits, bonds, treasury bills and money-market funds all earn Riba, so AAOIFI caps them at 30% of market capitalisation. Anika Therapeutics, Inc. stays inside that cap in the latest screening. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Anika Therapeutics, Inc. ANIK pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Anika Therapeutics, Inc. stock (ANIK) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar Riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Anika Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Anika Therapeutics, Inc. ANIK stock?

The dividend purification factor for Anika Therapeutics, Inc. (ANIK) stands at 100% in the September 2026 screening. In plain terms, 100% of a ANIK dividend is retained, and the remainder reflects incidental non-permissible income, typically interest on corporate cash, which Halal investors donate to charity (Tazkiyah). AAOIFI methodology asks for purification even on fully compliant stocks. The factor is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Anika Therapeutics, Inc. ANIK pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Anika Therapeutics, Inc. stock (ANIK) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Anika Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Anika Therapeutics (ANIK) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

Anika Therapeutics, Inc. (ANIK) is Shariah compliant in the September 2026 AAOIFI screening, passing all four AAOIFI screens. Dividends are purified using a factor of 100%. Tabadulat re-screens ANIK monthly, and the status can change when new financial data arrives.

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Employees:

288

Website:

https://www.anika.com

Market cap:

$288M

P/E ratio:

Dividend yield:

52-week range:

$8.37 - $22.88

Data as of:

3 September 2026

Screening history:

September 2026: PASS

Anika Therapeutics is a prominent player in the healthcare sector, specifically known for its focus on biotechnology and medical devices. The company is dedicated to developing, manufacturing, and commercializing therapeutic products for tissue protection, healing, and repair. It primarily targets musculoskeletal conditions, offering solutions for osteoarthritis pain management through viscosupplementation products. Anika Therapeutics also delves into regenerative medicine, providing products that aid in surgical repair and regenerative tissue growth. Before any of that matters to a Muslim investor, one question comes first: is Anika Therapeutics stock Halal?

Is Anika Therapeutics Shariah compliant?

Healthcare rarely troubles the activity screen; treating illness is permissible work. For Anika Therapeutics, the AAOIFI Shariah Standard No. 21 verdict turns on the balance sheet instead: research is capital hungry, and interest bearing debt and investments must each stay below 30% of market capitalisation.

Does Anika Therapeutics pass the business activity test?

Yes. In the September 2026 screening Anika Therapeutics holds an overall PASS, which a stock only earns when its core business clears the activity screen. Treating illness is permissible work; the scrutiny belongs to the financing behind it.

Is Anika Therapeutics' income Halal?

Yes, within AAOIFI's tolerance. Anika Therapeutics' income from non-permissible sources stays below 5% of revenue in the September 2026 screening, and the small impure portion is handled through purification: the factor of 100% tells holders of ANIK what share of each dividend to keep and what remainder to donate to charity.

Does Anika Therapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has ANIK re-screened every month, and the result above always shows the latest verdict.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read What is Halal Investing? A Guide to Halal Stocks and Islamic Finance

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.